Cedilla Therapeutics, a precision oncology biotechnology company, has raised an additional $25 million in an expansion of its Series B financing, bringing the total amount raised to $82.6 million.

The oversubscribed Series B expansion includes new investors RA Capital Management, Janus Henderson Investors, Woodline Partners LP and Logos Capital, along with participation from existing investor Third Rock Ventures.